BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rapiacta: Phase III amended

BioCryst amended the primary efficacy endpoint of the ongoing, double-blind, placebo-controlled Phase III BCX1812-301 trial to evaluate time to clinical resolution in a subset of about 160 patients not treated with neuraminidase inhibitors as standard of care. According to the biotech, the endpoint was changed to provide the best opportunity to show a statistically significant peramivir treatment...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >